NASDAQ:AQST Aquestive Therapeutics (AQST) Stock Price, News & Analysis $2.87 +0.02 (+0.70%) Closing price 04/25/2025 04:00 PM EasternExtended Trading$2.91 +0.04 (+1.39%) As of 04/25/2025 07:38 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Aquestive Therapeutics Stock (NASDAQ:AQST) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Aquestive Therapeutics alerts:Sign Up Key Stats Today's Range$2.79▼$2.9050-Day Range$2.37▼$3.2552-Week Range$2.20▼$5.80Volume669,185 shsAverage Volume1.53 million shsMarket Capitalization$283.76 millionP/E RatioN/ADividend YieldN/APrice Target$10.67Consensus RatingBuy Company OverviewAquestive Therapeutics, Inc. operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder. Its proprietary product candidates comprise Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; KYNMOBI, a sublingual film formulation of apomorphine for the treatment of episodic off-periods in Parkinson's disease; and Exservan, an oral soluble film formulation of riluzole for the treatment of amyotrophic lateral sclerosis. The company's proprietary pipeline of complex molecule product includes AQST-108, a sublingual film formulation delivering systemic epinephrine for the treatment of conditions other than anaphylaxis; and Anaphylm, an epinephrine sublingual film for the emergency treatment of allergic reactions, including anaphylaxis. In addition, it develops Adrenaverse, an epinephrine prodrug platform. The company was incorporated in 2004 and is headquartered in Warren, New Jersey.Read More… Aquestive Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks32nd Percentile Overall ScoreAQST MarketRank™: Aquestive Therapeutics scored higher than 32% of companies evaluated by MarketBeat, and ranked 765th out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.6 / 5Analyst RatingBuy Consensus RatingAquestive Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.14, and is based on 6 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageAquestive Therapeutics has only been the subject of 3 research reports in the past 90 days.Read more about Aquestive Therapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Aquestive Therapeutics are expected to decrease in the coming year, from ($0.46) to ($0.56) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Aquestive Therapeutics is -6.38, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Aquestive Therapeutics is -6.38, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about Aquestive Therapeutics' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted11.93% of the float of Aquestive Therapeutics has been sold short.Short Interest Ratio / Days to CoverAquestive Therapeutics has a short interest ratio ("days to cover") of 6.Change versus previous monthShort interest in Aquestive Therapeutics has recently decreased by 2.05%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAquestive Therapeutics does not currently pay a dividend.Dividend GrowthAquestive Therapeutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted11.93% of the float of Aquestive Therapeutics has been sold short.Short Interest Ratio / Days to CoverAquestive Therapeutics has a short interest ratio ("days to cover") of 6.Change versus previous monthShort interest in Aquestive Therapeutics has recently decreased by 2.05%, indicating that investor sentiment is improving. News and Social Media2.8 / 5News SentimentN/A News SentimentAquestive Therapeutics has a news sentiment score of 1.01. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.74 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Aquestive Therapeutics this week, compared to 3 articles on an average week.Search InterestOnly 5 people have searched for AQST on MarketBeat in the last 30 days. This is a decrease of -58% compared to the previous 30 days.MarketBeat Follows7 people have added Aquestive Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 250% compared to the previous 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Aquestive Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 7.85% of the stock of Aquestive Therapeutics is held by insiders.Percentage Held by InstitutionsOnly 32.45% of the stock of Aquestive Therapeutics is held by institutions.Read more about Aquestive Therapeutics' insider trading history. Receive AQST Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Aquestive Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address AQST Stock News HeadlinesAquestive Therapeutics to Participate in Piper Sandler Spring Biopharma SymposiumApril 9, 2025 | globenewswire.comAquestive Therapeutics Announces Positive Topline PK Results from its Pediatric Study and Completes the NDA Submission for Anaphylm™ (epinephrine) Sublingual FilmApril 3, 2025 | seekingalpha.comClaim Your FREE Protection GuideIn the final days of his first term, Trump quietly left open an "off the books" wealth-protection loophole hidden in the 6,871 pages of the IRS Tax Code... And since then, "in the know" patriots have quietly used this same "Trump loophole" to shield their life savings from the economic chaos. But with Trump now forcefully bringing back millions of manufacturing jobs from Mexico, China, and the entire BRICS anti-dollar coalition...April 26, 2025 | American Alternative (Ad)Aquestive Therapeutics (AQST) Gets a Buy from Lake StreetApril 2, 2025 | markets.businessinsider.comAquestive announces positive results from pediatric study for AnaphylmApril 2, 2025 | markets.businessinsider.comAquestive completes marketing application for Anaphylm in U.S.April 1, 2025 | msn.comAquestive Therapeutics: Oral Anaphylaxis NDA Opportunity Spells BuyMarch 25, 2025 | seekingalpha.comAquestive Therapeutics: Not For Me, But AttractiveMarch 24, 2025 | seekingalpha.comSee More Headlines AQST Stock Analysis - Frequently Asked Questions How have AQST shares performed this year? Aquestive Therapeutics' stock was trading at $3.56 at the beginning of 2025. Since then, AQST stock has decreased by 19.4% and is now trading at $2.87. View the best growth stocks for 2025 here. How were Aquestive Therapeutics' earnings last quarter? Aquestive Therapeutics, Inc. (NASDAQ:AQST) announced its quarterly earnings data on Wednesday, March, 5th. The company reported ($0.19) earnings per share for the quarter, missing the consensus estimate of ($0.14) by $0.05. The company earned $11.87 million during the quarter, compared to analyst estimates of $13.11 million. Read the conference call transcript. When did Aquestive Therapeutics IPO? Aquestive Therapeutics (AQST) raised $60 million in an IPO on Wednesday, July 25th 2018. The company issued 4,000,000 shares at $14.00-$16.00 per share. BMO Capital Markets and RBC Capital Markets acted as the underwriters for the IPO and Wedbush PacGrow and JMP Securities were co-managers. Who are Aquestive Therapeutics' major shareholders? Top institutional shareholders of Aquestive Therapeutics include Janney Montgomery Scott LLC (1.07%), Sugar Maple Asset Management LLC (0.03%), Trust Point Inc. (0.02%) and Penbrook Management LLC (0.02%). Insiders that own company stock include Alexander Mark Schobel, Cassie Jung, Daniel Barber, Peter E Boyd and Lori J Braender. View institutional ownership trends. How do I buy shares of Aquestive Therapeutics? Shares of AQST stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Aquestive Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Aquestive Therapeutics investors own include NVIDIA (NVDA), Broadcom (AVGO), Meta Platforms (META), Arista Networks (ANET), Adobe (ADBE), e.l.f. Beauty (ELF) and GE Aerospace (GE). Company Calendar Last Earnings3/05/2025Today4/26/2025Next Earnings (Estimated)5/06/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:AQST CIK1398733 Webwww.aquestive.com Phone(908) 941-1900FaxN/AEmployees160Year FoundedN/APrice Target and Rating Average Stock Price Target$10.67 High Stock Price Target$17.00 Low Stock Price Target$7.00 Potential Upside/Downside+271.7%Consensus RatingBuy Rating Score (0-4)3.14 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)($0.52) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-7,870,000.00 Net Margins-59.75% Pretax Margin-59.58% Return on EquityN/A Return on Assets-33.96% Debt Debt-to-Equity RatioN/A Current Ratio6.37 Quick Ratio5.91 Sales & Book Value Annual Sales$57.56 million Price / Sales4.93 Cash FlowN/A Price / Cash FlowN/A Book Value($1.59) per share Price / Book-1.81Miscellaneous Outstanding Shares98,871,000Free Float84,021,000Market Cap$283.76 million OptionableOptionable Beta2.59 2025 Gold Forecast: A Perfect Storm for DemandUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free Report This page (NASDAQ:AQST) was last updated on 4/26/2025 by MarketBeat.com Staff From Our Partners2025 could be "worse than the dot-com bust", says man who predicted 2008 banking crisisWhat's coming next to the U.S. market could be worse than anything we've ever seen before – worse than the dot...Stansberry Research | SponsoredTrump’s tariffs just split the AI market in twoTrump’s tariff just split the AI market – among others – in two. One group of AI companies—the ones relying...Traders Agency | SponsoredDonald Trump is about to free crypto from its chains …Sure enough, Bitcoin took off on the exact day Juan said it would. It's up more than 40% since the election...Weiss Ratings | SponsoredClaim Your FREE Protection GuideIn the final days of his first term, Trump quietly left open an "off the books" wealth-protection loophole hid...American Alternative | SponsoredJames Altucher: Do not invest in AI unless…I made millions during the crypto boom. Many “experts” are now saying… Artificial Intelligence opportuni...Paradigm Press | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowThe July 23rd Crypto Trigger Could Mark the Beginning of Bitcoin’s Next Big Move Bitcoin’s early 2024 ETF r...Crypto Swap Profits | SponsoredIt’s absolute chaos in Silicon Valley right now…If you missed out on the big boom in Nvidia… Listen up, because according to Nvidia's own CEO… Elon Musk...Brownstone Research | SponsoredTrump’s treachery Forget what the media tells you. Trump’s inner circle may be pushing a financial reset that mirrors moves from...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aquestive Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aquestive Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.